Background. Clostridioides difficile infection (CDI) is an important cause of morbidity and mortality and management continues to evolve. For laboratories that diagnose by detection of toxin gene, it is unclear whether reporting toxin production is additive to patient care. Furthermore, is there still a role for metronidazole (MNZ) given treatment guidelines now recommend vancomycin (VAN) as first-line therapy for non-severe cases? We analyzed cases of CDI in our hospital to assess outcomes of patients on MNZ vs. VAN and with or without toxin production.
Background. Clostridioides difficile infection (CDI) and recurrent CDI (rCDI) are associated with substantial economic burden, quality-of-life impairment, and increased morbidity and mortality. Fecal microbiota transplant (FMT) is an investigational, non-antibiotic approach to attempt to prevent recurrences in patients with multiple CDI. In controlled trials, efficacy rates of 62-76% have been reported with a single FMT, and up to 90% with multiple FMTs. This study evaluated real-world outcomes in patients with CDI, most of whom had a single FMT.
Methods. Data from the Optum ® de-identified Integrated Claims-Clinical dataset were extracted for patients with a first-observed CDI diagnosis between 4/2011 and 3/2018 that occurred within ±7 days of initial CDI antibiotics. Each patient had a > = 4-year look-back period with no CDI claims prior to the index episode. rCDI was defined as a subsequent antibiotic prescription between 7 and 365 days after the prior CDI episode. The proportion of patients with rCDI, use of FMT, and recurrences after FMT were reported.
Results. Of the 98,895 patients included in the analysis, 71,189 (72.0%) had one CDI episode, 27,706 (28.0%) had > = 1 rCDI, and 10,233 (10.4%) had multiple rCDI. The mean age was 64.2 years (56% > = 65 years), and 61% were female. Medicare was used by 48% of patients, and commercial insurance was used by 32%. A total of 522 (0.5%) patients (mean age, 61.9 years) received a total of 541 FMT procedures. 36% of the FMT procedures occurred after the first observed CDI episode, 22% after the 1st rCDI, and 42% after the second and/or subsequent rCDI episode. Of those who received FMT, 71.4% (n = 373) of patients had no subsequent CDI events by 3/2018.
Conclusion. As an investigational procedure, only a very small proportion of patients with CDI were identified as undergoing FMT, and the timing of the procedure for some patients may not have aligned with current guidance. This study provides data on real-world efficacy outcomes after a single FMT, with an efficacy rate of 71.4%, which is consistent with rates reported in controlled trials. A small number of patients received more than one FMT procedure, potentially due to treatment failures. Further research is needed to examine potential improvements in efficacy with multiple FMTs.
Disclosures. All authors: No reported disclosures. (CDI) . Carilion Roanoke Memorial Hospital (CRMH) implemented a clinical decision order set directing providers to initiate fidaxomicin for CDI in patients at high risk of recurrence. The purpose of this study was to assess the impact of fidaxomicin on patient outcomes.
First-line Fidaxomicin Use in
Methods. This quasi-experimental study included adults with a first episode or first recurrence of CDI before and after order set implementation. Patients receiving laxatives within 24 hours of testing and those with fulminant CDI were excluded. Preimplementation was defined as May 2017 to November 2017 and post-implementation as May 2018 to November 2018. The primary endpoint was recurrence (diarrhea and a positive GDH with toxin or PCR within 30 days post-treatment). Secondary endpoints were clinical cure (resolution of symptoms within 2 days of completing therapy), global cure (cure with no recurrence at 3 months), mortality, and readmissions. Partial courses of fidaxomicin (i.e., patients discharged on another agent) were also evaluated.
Results. A total of 282 patients were included. In the pre-group, 59.1% received metronidazole, 39.6% oral vancomycin, and 1.3% fidaxomicin. In the post-group, fidaxomicin use increased to 52.3% and oral vancomycin was 44.5%. There was a significant improvement in recurrence (30.2% vs 17.1%, P = 0.019). Global cure and CDI upon readmission also improved in the post-group (Table 1 ). In patients receiving partial courses of fidaxomicin, recurrence (9.3% vs 25%, P = 0.19), global cure (86% vs 75%, P = 0.44), and infection on readmission (28.6% vs 37.5%, P = 0.67) were similar.
Conclusion. Fidaxomicin as a first-line agent in high-risk CDI patients decreased recurrence and increased global cure.
Disclosures. All authors:
No reported disclosures. Background. Applying Artificial Intelligence techniques to healthcare data are gaining momentum. Early identification of patients at risk of surgical site infections is a major clinical goal. Our objective for this study was to determine whether deep learning AI techniques could identify patients at risk of intra-abdominal abscess development post-appendectomy using clinical data for pediatric patients undergoing appendectomy.
Using Artificial Neural Networks to Predict Intra-Abdominal Abscess Risk
Methods. A dataset of 1,574 patients classified by surgeons as negative (1,328) or positive (246) for Intra-Abdominal Abscess Post-Appendectomy for Appendicitis were selected from a database containing 6,127 patients less than 19 years-old who had appendectomy at our institution between 2009-2018. Demographic, clinical, and surgical information were extracted. 34 Independent variables were identified to be useful for the study. Using Random Forest methodology 12 variables with the highest influence on the outcome were selected for the final dataset. Data imputation (MICE algorithm) was used to replace missing data points. Two "Reproducible" Artificial Neural Networks with different architectures were developed to predict the risk of developing Intra-Abdominal Abscess Post-Appendectomy: Model (1) 12 Inputs, 3 hidden layers with 12 Neurons each, and 1 Output. Model (2) 12 Inputs, 2 hidden layers with 18 Neurons each, and 1 Output.
Results. For the 1,574 patients (80%-20% used as training and test sets), Model (1) achieved Accuracy of 89.84%, Sensitivity of ~ 70%, and Specificity of 93.61% on the test set while Model (2) achieved Accuracy of 84.13%, Sensitivity of 81.63%, and Specificity of 84.6%. The difference between the models is that in Model (2) we over sampled the minority class (using SMOTE algorithm) to balance both classes which helped the model to learn both classes without bias and improved sensitivity over Model (1).
Conclusion.
Deep learning algorithms applied to enough clinical variables can identify patients with high probability for the risk of developing intra-abdominal abscess post-appendectomy. While further test sets are necessary to validate the models, Artificial Neural Networks can be an important addition to current
